176 related articles for article (PubMed ID: 17210123)
1. Inhibition of HIV-1 infection by synthetic peptides derived CCR5 fragments.
Imai M; Baranyi L; Okada N; Okada H
Biochem Biophys Res Commun; 2007 Feb; 353(4):851-6. PubMed ID: 17210123
[TBL] [Abstract][Full Text] [Related]
2. Solution structure of LC5, the CCR5- derived peptide for HIV-1 inhibition.
Miyamoto K; Togiya K; Kitahara R; Akasaka K; Kuroda Y
J Pept Sci; 2010 Apr; 16(4):165-70. PubMed ID: 20196122
[TBL] [Abstract][Full Text] [Related]
3. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].
Azevedo-Pereira JM; Santos-Costa Q
Acta Med Port; 2008; 21(5):497-504. PubMed ID: 19187693
[TBL] [Abstract][Full Text] [Related]
4. A killer mimotope with therapeutic activity against AIDS-related opportunistic micro-organisms inhibits ex-vivo HIV-1 replication.
Casoli C; Pilotti E; Perno CF; Balestra E; Polverini E; Cassone A; Conti S; Magliani W; Polonelli L
AIDS; 2006 Apr; 20(7):975-80. PubMed ID: 16603848
[TBL] [Abstract][Full Text] [Related]
5. Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4.
Kazmierski WM; Kenakin TP; Gudmundsson KS
Chem Biol Drug Des; 2006 Jan; 67(1):13-26. PubMed ID: 16492145
[TBL] [Abstract][Full Text] [Related]
6. Genotypic coreceptor analysis.
Sierra S; Kaiser R; Thielen A; Lengauer T
Eur J Med Res; 2007 Oct; 12(9):453-62. PubMed ID: 17933727
[TBL] [Abstract][Full Text] [Related]
7. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
Deng Y; Zheng Q; Ketas TJ; Moore JP; Lu M
Biochemistry; 2007 Apr; 46(14):4360-9. PubMed ID: 17371053
[TBL] [Abstract][Full Text] [Related]
8. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors.
Yoshimura K; Shibata J; Kimura T; Honda A; Maeda Y; Koito A; Murakami T; Mitsuya H; Matsushita S
AIDS; 2006 Oct; 20(16):2065-73. PubMed ID: 17053352
[TBL] [Abstract][Full Text] [Related]
9. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
[TBL] [Abstract][Full Text] [Related]
10. In vitro inhibition of R5 HIV-1 infectivity by X4 V3-derived synthetic peptides.
Baritaki S; Dittmar MT; Spandidos DA; Krambovitis E
Int J Mol Med; 2005 Aug; 16(2):333-6. PubMed ID: 16012771
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of the entry of HIV into host cells.
Meanwell NA; Kadow JF
Curr Opin Drug Discov Devel; 2003 Jul; 6(4):451-61. PubMed ID: 12951808
[TBL] [Abstract][Full Text] [Related]
12. Anti-HIV activity and conformational studies of peptides derived from the C-terminal sequence of SDF-1.
Dettin M; Pasquato A; Scarinci C; Zanchetta M; De Rossi A; Di Bello C
J Med Chem; 2004 Jun; 47(12):3058-64. PubMed ID: 15163187
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a chemokine receptor CCR5-negative T cell line and its use in determining human immunodeficiency virus type 1 phenotype.
Binninger-Schinzel D; Müller D; Wolf T; Krause B; Meye B; Winskowsky G; Raupp S; Norley S; Brodt R; Werner A
J Med Virol; 2008 Feb; 80(2):192-200. PubMed ID: 18098144
[TBL] [Abstract][Full Text] [Related]
14. Antisense homology boxes in C5a receptor and C5a anaphylatoxin: a new method for identification of potentially active peptides.
Baranyi L; Campbell W; Okada H
J Immunol; 1996 Nov; 157(10):4591-601. PubMed ID: 8906838
[TBL] [Abstract][Full Text] [Related]
15. Structure-function relationship of novel X4 HIV-1 entry inhibitors - L- and D-arginine peptide-aminoglycoside conjugates.
Hegde R; Borkow G; Berchanski A; Lapidot A
FEBS J; 2007 Dec; 274(24):6523-36. PubMed ID: 18028446
[TBL] [Abstract][Full Text] [Related]
16. [CCR5, a new target of anti-HIV drugs].
Han YX; Jiang JD
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Oct; 25(5):635-9. PubMed ID: 14650176
[TBL] [Abstract][Full Text] [Related]
17. Chemokine receptor-5 (CCR5) is a receptor for the HIV entry inhibitor peptide T (DAPTA).
Polianova MT; Ruscetti FW; Pert CB; Ruff MR
Antiviral Res; 2005 Aug; 67(2):83-92. PubMed ID: 16002156
[TBL] [Abstract][Full Text] [Related]
18. Electrostatic modeling of peptides derived from the V3-loop of HIV-1 gp120: implications of the interaction with chemokine receptor CCR5.
Morikis D; Rizos AK; Spandidos DA; Krambovitis E
Int J Mol Med; 2007 Mar; 19(3):343-51. PubMed ID: 17273779
[TBL] [Abstract][Full Text] [Related]
19. CCR5 antagonists: a new tool in fighting HIV.
Jülg B; Goebel FD
J HIV Ther; 2005 Dec; 10(4):68-71. PubMed ID: 16519245
[TBL] [Abstract][Full Text] [Related]
20. Molecular characterization of the env gene of two CCR5/CXCR4-independent human immunodeficiency 2 primary isolates.
Santos-Costa Q; Parreira R; Moniz-Pereira J; Azevedo-Pereira JM
J Med Virol; 2009 Nov; 81(11):1869-81. PubMed ID: 19774680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
